Replies to post #11298 on Biotech Values

[DewDiligence]

Re: Agennix

>>But that's a huge drop in the PFS increase when you go from the ITT group (n=110) to the 100 patient group.<<

They need to disclose how the “100 prospectively defined evaluable patients” were selected.